SPONSOR

Sun Yat-sen University

Total Trials

Recruiting

Phases

Phase 2, Phase 1, Phase 2, Phase 4, Phase 3, Phase 1, Phase 2, Phase 3

Conditions studied: Ewing Sarcoma BRAF V600 Colorectal Cancer Nasopharyngeal Carcinoma Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)Hepatocellular Carcinoma Microwave Ablation Liver Cancer Lenvatinib Recurrent Tumor Stage III Non-small Cell Lung Cancer

Sun Yat-sen University is a clinical research sponsor with 46 registered studies on ClinicalTrials.gov, of which 46 are actively recruiting participants. Research covers conditions including Ewing Sarcoma, BRAF V600 Colorectal Cancer, Nasopharyngeal Carcinoma, Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL).

The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Sun Yat-sen University

How many clinical trials has Sun Yat-sen University sponsored?

ClinicalMetric currently tracks 46 clinical trials sponsored by Sun Yat-sen University, of which 46 are actively recruiting participants. These trials cover conditions including Ewing Sarcoma, BRAF V600 Colorectal Cancer, Nasopharyngeal Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Sun Yat-sen University research focus on?

Sun Yat-sen University clinical trials span Ewing Sarcoma, BRAF V600 Colorectal Cancer, Nasopharyngeal Carcinoma, Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL), Hepatocellular Carcinoma, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Sun Yat-sen University clinical trial?

To participate in a Sun Yat-sen University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sun Yat-sen University trials with current recruitment status updated daily.

Sun Yat-sen University

Frequently Asked Questions — Sun Yat-sen University

Clinical Trials by Sun Yat-sen University

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

Comparison of Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)

The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Effects of Digital Therapeutic in Whole Process Management of Lung Cancer

Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study

Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

Safety and Efficacy of Pucotenlimab in pLECC

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma